Moderna is now expecting 2025 research and development costs of about $4.1 billion and selling, general and administrative costs of about $1.1 billion. Cost of sales is expected to come to about $1.2 ...

Blaize's innovative product pipeline, built on its full-stack programmable processor architecture suite and software platform for AI processing, has resulted in an increasingly robust and growing ...

Blaize’s innovative product ... analysis is clear and in no way misleading or deceptive. To further protect the integrity of our editorial content, we keep a strict separation between our sales ...

TD Cowen began coverage of Crinetics Pharmaceuticals (NASDAQ:CRNX) with a Buy rating, citing the company's strong position in ...

As businesses navigate increasingly complex economic pressures, the demand for more reliable and sophisticated sales ...

Today, majors across segments including Godfrey Phillips, United Breweries, Senco Gold, Reliance Infra, Hindalco, Healthcare ...

The Media Online’s weekly round up of people, account and business moves in media. This week’s BIG move: Havas Media ...

Ipsen expects total sales growth of more than 5% at constant exchange rates in 2025, supported by the continued expansion of products like IQIRVO, ONIVYDE, and Bylvay. However, Somatuline faces ...

One of the most significant news items involving Vertex isn't reflected in the company's numbers just yet. Vertex's non-opioid pain relief drug, Journavx, received FDA approval on Jan. 30. The drug is ...

Biogen Inc. CEO Christopher Viehbacher gave investors an overview of what type of deals the company is looking for Wednesday ...